These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16272755)

  • 1. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus.
    Matsui-Sakata A; Ohtani H; Sawada Y
    Drug Metab Pharmacokinet; 2005 Oct; 20(5):368-78. PubMed ID: 16272755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase.
    Montastruc F; Palmaro A; Bagheri H; Schmitt L; Montastruc JL; Lapeyre-Mestre M
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1556-65. PubMed ID: 26256010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes.
    Silvestre JS; Prous J
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):289-304. PubMed ID: 16082416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H1-histamine receptor affinity predicts weight gain with antidepressants.
    Salvi V; Mencacci C; Barone-Adesi F
    Eur Neuropsychopharmacol; 2016 Oct; 26(10):1673-7. PubMed ID: 27593622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?
    Deng C; Weston-Green K; Huang XF
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):1-4. PubMed ID: 19922755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Kroeze WK; Hufeisen SJ; Popadak BA; Renock SM; Steinberg S; Ernsberger P; Jayathilake K; Meltzer HY; Roth BL
    Neuropsychopharmacology; 2003 Mar; 28(3):519-26. PubMed ID: 12629531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.
    Richelson E; Souder T
    Life Sci; 2000 Nov; 68(1):29-39. PubMed ID: 11132243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies.
    Haraguchi K; Ito K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1997 Jun; 25(6):675-84. PubMed ID: 9193868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions.
    Sekine Y; Rikihisa T; Ogata H; Echizen H; Arakawa Y
    Eur J Clin Pharmacol; 1999 Oct; 55(8):583-7. PubMed ID: 10541776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study focuses in on potential cause of antipsychotic-induced diabetes.
    O'Neill MF
    Drug News Perspect; 2005 Oct; 18(8):481-2. PubMed ID: 16391716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication.
    Vehof J; Risselada AJ; Al Hadithy AF; Burger H; Snieder H; Wilffert B; Arends J; Wunderink L; Knegtering H; Wiersma D; Cohen D; Mulder H; Bruggeman R
    Psychopharmacology (Berl); 2011 Jul; 216(2):257-65. PubMed ID: 21336576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.
    Seeman P; Tallerico T
    Mol Psychiatry; 1998 Mar; 3(2):123-34. PubMed ID: 9577836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
    Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
    Matsui-Sakata A; Ohtani H; Sawada Y
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):187-99. PubMed ID: 15988121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bodyweight gain with atypical antipsychotics. A comparative review.
    Wetterling T
    Drug Saf; 2001 Jan; 24(1):59-73. PubMed ID: 11219487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of prolactin in antipsychotic-mediated association of schizophrenia and type 2 diabetes.
    Oberweis B; Gragnoli C
    J Cell Physiol; 2012 Aug; 227(8):3001-6. PubMed ID: 22105468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.
    Lian J; Huang XF; Pai N; Deng C
    Pharmacol Res; 2016 Apr; 106():51-63. PubMed ID: 26892184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.